CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries
- 15 November 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 28 (6), 566-580
- https://doi.org/10.1038/s41417-020-00256-7
Abstract
Continued advancements in CRISPR-Cas systems have accelerated genome research. Use of CRISPR-Cas in cancer research has been of great interest that is resulting in development of orthogonal methods for drug target validations and discovery of new therapeutic targets through genome-wide screens of cancer cells. CRISPR-based screens have also revealed several new cancer drivers through alterations in tumor suppressor genes (TSGs) and oncogenes inducing resistance to targeted therapies via activation of alternate signaling pathways. Given such dynamic status of cancer, we review the application of CRISPR-Cas in non-small cell lung cancer (NSCLC) for development of mutant models, drug screening, target validation, novel target discoveries, and other emerging potential applications. In addition, CRISPR-based approach for development of novel anticancer combination therapies is also discussed in this review.This publication has 143 references indexed in Scilit:
- LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancerCell Death & Disease, 2013
- TCF3, a novel positive regulator of osteogenesis, plays a crucial role in miR-17 modulating the diverse effect of canonical Wnt signaling in different microenvironmentsCell Death & Disease, 2013
- TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic TransformationMolecular Cell, 2011
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNature Reviews Cancer, 2010
- Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancerBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitorsInternational Journal of Cancer, 2009
- A comprehensive pathway map of epidermal growth factor receptor signalingMolecular Systems Biology, 2005
- Fas receptor‐mediated apoptosis: a clinical application?The Journal of Pathology, 2001